Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Dryden-Peterson, Scott

Brigham And Women'S Hospital
United States

Botswana CASCADE Clinical Trials Site 3UG1CA275416-04S1 Maria Silvina Frech, Ph.D., M.S.
Duan, Bin

University Of Nebraska Medical Center
United States

Flupirtine Analogue Synthesis and Screening for the Treatment of Chemotherapy-Induced Neuropathic Pain 1R21CA298918-01 Rachel Altshuler, Ph.D.
Duan, Bin

University Of Nebraska Medical Center
United States

Flupirtine Analogue Synthesis and Screening for the Treatment of Chemotherapy-Induced Neuropathic Pain 1R21CA298918-01 Rachel Altshuler, Ph.D.
Duan, Bin

University Of Nebraska Medical Center
United States

Flupirtine Analogue Synthesis and Screening for the Treatment of Chemotherapy-Induced Neuropathic Pain 1R21CA298918-01 Rachel Altshuler, Ph.D.
Duncavage, Eric J

Washington University
United States

Whole Genome Sequencing for Genomic Evaluation and Risk Stratification of Patients with Myelodysplastic Syndromes 4UH3CA272904-02 Nicholas Hodges, Ph.D.
Duvall, Adam S.

University Of Chicago
United States

Tailoring a fun and engaging tech-assisted cognitive behavioral therapy program for adolescents and young adults with hematological malignancies: A planning grant 1R34CA297498-01 Brennan Streck, Ph.D., RN, M.P.H.
Duvall, Adam S.

University Of Chicago
United States

Tailoring a fun and engaging tech-assisted cognitive behavioral therapy program for adolescents and young adults with hematological malignancies: A planning grant 1R34CA297498-01 Brennan Streck, Ph.D., RN, M.P.H.
Duvall, Adam S.

University Of Chicago
United States

Tailoring a fun and engaging tech-assisted cognitive behavioral therapy program for adolescents and young adults with hematological malignancies: A planning grant 1R34CA297498-01 Brennan Streck, Ph.D., RN, M.P.H.
Eastham, James A

Sloan-Kettering Inst Can Research
United States

Influence of intra-individual variability in serial screening samples on clinical decision-making for risk stratification and biopsy by a single PSA and additional markers 5U01CA266535-04 Claire Zhu, Ph.D.
Eibl, Guido Erwin Michael

University Of California Los Angeles
United States

Chemoprevention and mechanisms of obesity-promoted pancreatic adenocarcinoma 5P01CA236585-05
Eickhoff, Jens

University Of Wisconsin-Madison
United States

CP-CTNet Coordinating Center 1UG1CA304955-01 Donald Johnsey
Eisenmann, Eric Daniel

Ohio State University
United States

Damage-associated molecular patterns in chemotherapy toxicity 1R37CA299879-01 Rachel Altshuler, Ph.D.
Eisenmann, Eric Daniel

Ohio State University
United States

Damage-associated molecular patterns in chemotherapy toxicity 1R37CA299879-01 Rachel Altshuler, Ph.D.
El-Bayoumy, Karam E

Pennsylvania State Univ Hershey Med Ctr
United States

Chemoprevention by Black Raspberry of Oral Cancer Induced by Tobacco Carcinogens: Translational Studies 5R01CA173465-10 Gabriela Riscuta, M.D., CNS
El-Serag, Hashem B

Baylor College Of Medicine
United States

Prevention of Hepatocellular Carcinoma Related to Metabolic Syndrome 5P01CA263025-04 Asad Umar, D.V.M., Ph.D.